Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen Inc has demonstrated a positive growth trajectory with a 13.6% compound annual growth rate (CAGR) in revenue since 2020, highlighting the company's consistent performance in the peripheral nerve regeneration market. The increasing reimbursement rates for allograft procedures, including a 138% rise for ambulatory surgery centers since 2019, indicate a strengthening market environment that could enhance the company's profitability. Furthermore, the potential for sustainable profitability by 2026, driven by expanding market penetration in various surgical applications, further supports a favorable outlook for the company's stock.

Bears say

Axogen Inc. faces numerous risks that contribute to a negative outlook on its stock, including potential lower-than-expected sales growth stemming from competition, regulatory hurdles, and technological advancements that could render its products obsolete. The company has a history of net losses and is highly dependent on key management and market acceptance, while increased competition from alternative nerve repair products poses a threat to its revenue and market share. Additionally, uncertainties surrounding the regulatory approval process for its flagship product, Avance, along with challenges related to scaling operations and managing supply chain issues, further undermine Axogen's growth prospects and sustainable profitability.

AxoGen (AXGN) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 9 analysts, AxoGen (AXGN) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.